The AVEO Oncology management team comprises executives with years of oncology and pharmaceutical industry experience and expertise, and a proven track record for success in bringing important new therapies to patients.
President and CEO
Tuan Ha-Ngoc has served as president and chief executive officer of AVEO and as a member of our board of directors since June 2002 and has more than 25 years of senior leadership experience in the biotech industry. From 1999 to 2002, he was co-founder, president and chief executive officer of deNovis, Inc., an enterprise-scale software development company for the automation of healthcare administrative functions. From 1998 to 1999, Mr. Ha-Ngoc was corporate vice president of strategic development for Wyeth, following Wyeth’s acquisition of Genetics Institute, where Mr. Ha-Ngoc served from 1984 to 1997 as executive vice president with responsibility for corporate development, commercial operations and European and Japanese operations. Mr. Ha-Ngoc serves on the boards of a number of academic organizations, including the Harvard School of Dental Medicine, and the MIT Koch Institute of Integrative Cancer Research. He holds an M.B.A. from INSEAD and an M.A. in pharmacy from the University of Paris, France.
CHIEF BUSINESS OFFICER
Michael P. Bailey brings more than 20 years of experience in the pharmaceutical industry to AVEO as the company’s chief commercial officer. In this role he oversees marketing, sales, new product strategy, business analytics, commercial operations, health systems and patient services. He joined AVEO in 2010 from Synta Pharmaceuticals, where he served as senior vice president, business development and chief commercial officer since 2008. Prior to joining Synta, Mr. Bailey led ImClone's Worldwide Commercial Organization. During his nine year tenure at ImClone he was responsible for commercial aspects for the planning and launch of Erbitux across multiple indications. In addition, Mr. Bailey was a key member of the strategic leadership committees for ImClone and its North American and worldwide partnerships. Prior to joining ImClone, Mr. Bailey managed the cardiovascular development portfolio at Genentech, Inc. and was a key member of their global commercial partnership teams. Mr. Bailey started his career in the pharmaceutical industry as part of SmithKline Beecham's Executive Marketing Development Program, where he held a variety of commercial roles, including sales, strategic planning, and product management. Mr. Bailey received a B.S. in psychology from St. Lawrence University and an M.B.A. in international marketing from the University of Notre Dame Graduate School of Business.
William Slichenmyer, M.D., Sc.M.
CHIEF MEDICAL OFFICER
Bill Slichenmyer has served as AVEO’s chief medical officer since September 2009. Dr. Slichenmyer’s pharmaceutical industry career spans 18 years in both large and small biopharmaceutical companies where he has contributed to the development of anticancer agents of many classes including cytotoxic drugs, monoclonal antibodies, oligonucleotide therapeutics and targeted small molecules. Prior to joining AVEO, Dr. Slichenmyer served as chief medical officer at Merrimack Pharmaceuticals from 2007 to September 2009. Before his tenure at Merrimack, Dr. Slichenmyer spent seven years at Pfizer in roles that included global head of oncology clinical development, where he led the development and FDA approval process of the Sutent program, as well as positions in medical affairs and regulatory affairs. Prior to joining Pfizer, Dr. Slichenmyer held various senior level positions at Parke-Davis Pharmaceuticals, Hybridon Inc., Bristol-Myers Squibb Pharmaceutical Research Institute and Burroughs Wellcome. Dr. Slichenmyer holds a B.A. and M.D. from Case Western Reserve University. He received postgraduate training in pathology and internal medicine, followed by subspecialty training in medical oncology at the Johns Hopkins Oncology Center, where he also earned a Sc.M. degree in clinical investigation.
Jeno Gyuris, Ph.D.
CHIEF SCIENTIFIC OFFICER
Jeno Gyuris was named senior vice president, chief scientific officer of AVEO in 2012 and oversees the company’s drug discovery and translational activities, focused on monoclonal antibodies. Dr. Gyuris joined AVEO in 2003 and served as vice president, molecular technologies until January 2007, and served as senior vice president, drug discovery from January 2007 to January 2010. In 2010, he was named senior vice president, head of research. Prior to joining AVEO, Dr. Gyuris spent nearly 10 years at GPC Biotech AG, formerly Mitotix Inc., where he held positions of increasing responsibility, most recently vice president of molecular technologies. During his tenure at GPC Biotech, he initiated several target and drug discovery programs, invented a number of technology platforms and played a key role in the commercialization of those technologies. Dr. Gyuris has received several research fellowships in Europe and the United States, and is the author of numerous patents and publications. He received a Ph.D. from University of Szeged, Szeged, Hungary.
Joseph Vittiglio, Esq.
SENIOR VICE PRESIDENT, GENERAL COUNSEL
Joseph Vittiglio joined AVEO in 2007 and has more than 15 years experience in corporate and securities law, with a particular focus in the biotech and pharmaceutical industries. Prior to joining AVEO, Mr. Vittiglio was the director of corporate legal affairs of Oscient Pharmaceuticals from 2005 through 2007. From 1998 through 2005, Mr. Vittiglio was a senior attorney at the Boston law firm of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., where his practice focused principally in the life science and technology industries, working on collaborative arrangements, corporate partnering, registered public offerings, mergers and acquisitions and venture financings. Mr. Vittiglio sits on the Board of Directors of the Casa Monte Cassino in Boston and on the Board of Directors Lynnfield Youth Soccer. Mr. Vittiglio holds a degree in International Relations from Tufts University and graduated from Northeastern University School of Law in 1996.